Progenra, Inc

Ubiquitin-based drug discovery, such as Protein Targeting Chimeras (PROTAC) is at the exciting initial stages. PROTAC drugs are, hetero-bifunctional small molecules that bind at one end to an E3 ligase and at the other end to a protein meant to be degraded for therapeutic effect, has added a new dimension to proteostasis-based therapy. PROTACs have several advantages over simple DUB or E3 inhibitors or activators, including catalytic mechanism of action, reduced susceptibility to resistance owing to target mutation, and pharmacologic activity at concentrations lower than those usually needed for simple enzyme effectors. Progenra is developing a new class of PROTAC...

Oncology,cns,inflammatory diseases,neurogenerative diseases,ubipro,and protac

Progenra, inc operates in the Biotechnology industry.

Progenra, inc's revenue is 11m - 100m

Progenra, inc has 11 - 50 employees.